AFT Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
AFT Pharmaceuticals has been growing earnings at an average annual rate of 9.7%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 15.6% per year. AFT Pharmaceuticals's return on equity is 13.6%, and it has net margins of 5.8%.
Key information
9.7%
Earnings growth rate
9.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.6% |
| Revenue growth rate | 15.6% |
| Return on equity | 13.6% |
| Net Margin | 5.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
AFT Pharmaceuticals Limited (NZSE:AFT) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 17
It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year
Jul 26AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
May 25Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?
May 22Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?
Oct 17Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?
May 23Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?
Dec 01We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise
Jul 30With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For
Jun 02Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?
Mar 20A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation
Feb 13
Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 23Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?
Jan 02Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?
Dec 12AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 21Revenue & Expenses Breakdown
How AFT Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 199 | 12 | 62 | 8 |
| 30 Jun 24 | 197 | 14 | 60 | 7 |
| 31 Mar 24 | 195 | 16 | 58 | 6 |
| 31 Dec 23 | 185 | 13 | 57 | 6 |
| 30 Sep 23 | 175 | 11 | 56 | 5 |
| 30 Jun 23 | 166 | 11 | 53 | 4 |
| 31 Mar 23 | 157 | 11 | 49 | 4 |
| 31 Dec 22 | 149 | 14 | 46 | 4 |
| 30 Sep 22 | 141 | 17 | 42 | 4 |
| 30 Jun 22 | 135 | 18 | 40 | 4 |
| 31 Mar 22 | 130 | 20 | 38 | 4 |
| 31 Dec 21 | 125 | 15 | 38 | 3 |
| 30 Sep 21 | 120 | 11 | 39 | 3 |
| 30 Jun 21 | 116 | 9 | 38 | 2 |
| 31 Mar 21 | 113 | 8 | 37 | 2 |
| 31 Dec 20 | 110 | 5 | 36 | 1 |
| 30 Sep 20 | 107 | 3 | 36 | 0 |
| 30 Jun 20 | 107 | 7 | 37 | 0 |
| 31 Mar 20 | 106 | 12 | 37 | 0 |
| 31 Dec 19 | 100 | 11 | 36 | 0 |
| 30 Sep 19 | 94 | 11 | 35 | 1 |
| 30 Jun 19 | 89 | 4 | 35 | 1 |
| 31 Mar 19 | 85 | -3 | 35 | 1 |
| 31 Dec 18 | 84 | -7 | 38 | 2 |
| 30 Sep 18 | 83 | -11 | 40 | 4 |
| 30 Jun 18 | 82 | -12 | 39 | 5 |
| 31 Mar 18 | 81 | -14 | 39 | 7 |
| 31 Dec 17 | 79 | -14 | 37 | 8 |
| 30 Sep 17 | 76 | -14 | 34 | 10 |
| 30 Jun 17 | 73 | -16 | 34 | 10 |
| 31 Mar 17 | 69 | -18 | 34 | 9 |
| 31 Dec 16 | 67 | -18 | 33 | 8 |
| 30 Sep 16 | 64 | -18 | 32 | 8 |
| 30 Jun 16 | 64 | -16 | 30 | 7 |
| 31 Mar 16 | 64 | -13 | 29 | 6 |
| 31 Dec 15 | 63 | -13 | 27 | 5 |
| 30 Sep 15 | 62 | -13 | 26 | 4 |
| 30 Jun 15 | 59 | -13 | 25 | 4 |
| 31 Mar 15 | 56 | -13 | 24 | 5 |
| 31 Mar 14 | 49 | -1 | 16 | 2 |
Quality Earnings: AFT has high quality earnings.
Growing Profit Margin: AFT's current net profit margins (5.8%) are lower than last year (6.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AFT's earnings have grown by 9.7% per year over the past 5 years.
Accelerating Growth: AFT's earnings growth over the past year (6.3%) is below its 5-year average (9.7% per year).
Earnings vs Industry: AFT earnings growth over the past year (6.3%) did not outperform the Pharmaceuticals industry 26.6%.
Return on Equity
High ROE: AFT's Return on Equity (13.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:38 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AFT Pharmaceuticals Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Jack Crowley | Credit Suisse |
| Soo Romanoff | Edison Investment Research |